Objective: We aimed to evaluate the combined effects of HIV and APOE e4 allele(s) on glial metabolite levels, and on known cognitive deficits associated with either condition, across the ages.
pleiotropy, because the APOE e4 allele(s) 5, 11 has a negative effect on cognition only in older individuals.
Because HAND is often difficult to assess in the clinical setting, 12 understanding how APOE e4 allele(s) affects brain injury in patients with HIV may be useful for prognostication or early identification of individuals at risk for HAND. Therefore, we aimed to evaluate whether APOE e4 allele(s) exacerbates brain metabolite or cognitive abnormalities in HIV1 subjects and whether age further interacts with these variables. We hypothesized that HIV1 subjects with APOE e4 would have greater cognitive deficits and glial metabolite abnormalities on proton magnetic resonance spectroscopy (MRS) than subjects without e41 and that such abnormalities would be present even in the younger subjects.
METHODS Standard protocol approvals, registrations, and patient consents. The protocol was approved by the institutional review boards at the University of Hawaii and at the Queen's Medical Center. Three hundred ninety subjects from the local community were recruited between December 2004 and August 2012 and provided oral and written consents before the assessments.
Research participants. Three hundred thirty-eight participants fulfilled the study criteria and 177 with complete and acceptable datasets were included in this study (97 seronegative [SN] subjects: aged 44. 7 (table 1) . All subjects were 18 years or older and able to provide informed consent. All were tested to ensure HIV serostatus. HIV1 subjects were either not taking ARVs or stable on ARVs for .6 months (ARVstable) and had a nadir CD4 cell count ,500/mm 3 . Exclusion criteria for all subjects included the following: (1) chronic medical or neuropsychiatric illnesses that might confound the outcome variables; (2) significant abnormalities on laboratory measures that might indicate a severe metabolic disorder or organ failure; (3) history of head trauma with loss of consciousness .30 minutes; (4) history of drug dependence according to DSM-IV criteria, except for tobacco; (5) positive urine toxicology for common drugs of abuse, except for D9-tetrahydrocannabinol, because many were using medicinal marijuana; and (6) any contraindications for MRI.
Neuropsychological tests. Each participant performed a battery of neuropsychological tests sensitive for detecting cognitive deficits in patients with HIV infection. The tests evaluated 7 cognitive domains (see table 2 ). In addition, depressive symptoms were assessed using the Center for Epidemiological Studies-Depression Scale. Twenty-nine (36.3%) of the HIV1 subjects were diagnosed with HAND according to the Updated Research Nosology, 13 including clinical assessments with self-report, neurologic evaluations, Functional Activities Questionnaire, and Karnofsky score. Eleven had asymptomatic neurocognitive impairment, 17 minor neurocognitive disorder, and one had HIV-associated dementia; the remaining 51 HIV subjects had normal cognition. Conversely, only 15 (15.5%) SN controls had cognitive deficits comparable to HAND. APOE e genotyping. Genomic DNA was isolated from the human blood sample by using the DNeasy Blood and Tissue kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Genomic DNA concentration and purity were assessed with the Nanodrop 1000 (Thermo Scientific, West Palm Beach, FL). APOE e genotypes were determined by PCR-based RFLP (restriction fragment length polymorphism). First, a 218-base pair fragment of the APOE gene was amplified using these primers: forward sequence (TCCAAGGAGCTGCAGGCGGCGCA) and reverse sequence (GCCCCGGCCTGGTACACTGCCA); afterward, the PCR fragment was digested with restriction enzymes AflIII (5,000 U/mL) and HaeII (20,000 U/mL), 103 buffer 3, and 103 bovine serum albumin (New England BioLabs, Ipswich, MA) for 12 hours at 37°C. Digest products were resolved on 4% agarose gel. APOE e genotype was confirmed for each subject using the Illumina BeadXpress scanner (iGenix, Bainbridge Island, WA).
MRI and MRS.
All magnetic resonance studies were performed on a 3T MR scanner (Tim Trio; Siemens Medical Solutions, Erlangen, Germany) with an 8-or 12-channel head coil. The MRI protocol included a 3-plane localizer (repetition time [TR]/echo time [TE] 5 20/5 milliseconds, 1-average), a sagittal 3-dimensional magnetization-prepared rapid-acquisition gradient echo (MP-RAGE) (TR/TE/inversion time 5 2,200/4.91/1,000 milliseconds; 1-average; 208 3 256 3 160 matrix), and an axial fluid-attenuated inversion recovery sequence (TR/TE 5 10,000/ 85 milliseconds; 1-average; 205 3 320 3 28 matrix). These structural images were evaluated for possible brain lesions and used to prescribe the MRS voxels and for gray-white matter segmentation. Proton MRS was acquired from 4 approximately 8-mL brain regions: basal ganglia, parietal gray matter, frontal white matter, and anterior cingulate gray matter (figure 1). A PRESS (point resolved spectroscopy) acquisition sequence was used (64 averages, TR/TE 5 3,000/30 milliseconds, bandwidth 1,200 Hz, 4 dummy scans, 8-step phase cycling), and the T2 decay of the water signal was measured at 10 different echo times.
MRS data were processed using a customized spectral analysis package of LCModel to determine concentrations of major metabolites, including the glial metabolites total creatine (tCr) and myo-inositol (MI). The metabolite concentrations were corrected for the variable percentages of CSF, gray matter, and white matter in each voxel, although no group differences were found for these variables. The water T2-decay data were used to calculate the % CSF in each voxel. 14 The proportion of gray and white matter in each voxel was determined by segmenting the high-resolution MP-RAGE scans using FMRIB's Automated Segmentation Tool (FAST, version 4.1) for cortical voxels and FMRIB's Integrated Registration and Segmentation Tool (FIRST, version 1.2) for subcortical structures. Each spectrum was visually inspected and met the following criteria from the LCModel fit: (1) full width at half maximum ,0.10 ppm (,0.12 ppm for basal ganglia), (2) signal-to-noise ratio .7, and (3) Cramér-Rao bounds for each metabolite #25%.
Statistical methods. Statistical analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC). Two-way analysis of variance and multiple contingency tables were used to compare clinical variables between HIV1 and SN subjects, with and without APOE e4 allele(s). Two-way analyses of covariance, including age, education, or scanner software version as covariate, were used to test the independent and interactive effects of HIV status and APOE e4 status (at least one APOE e41 allele) on brain metabolites and cognitive function. Relationships among age, cognitive performance, and brain metabolites that showed group differences were explored using linear regression. Because Bonferroni correction tends to be overly conservative and we focused our analyses based on prior knowledge of altered glial metabolites (i.e., MI and tCr) in 3 brain regions (frontal white matter, parietal cortex, and basal ganglia) and abnormal cognitive domains in HIV patients, p values ,0.01 were considered statistically significant and p values ,0.05 were considered trends for significance.
RESULTS
Our analysis focused on the effects of HIV and APOE e4 status, their combined or interactive effects, and age-dependent changes on the glial metabolites (MI and tCr levels) and cognitive performance. Furthermore, we evaluated the relationships between MI levels that showed these effects in the 3 brain regions and cognitive performance.
Clinical characteristics. The SN and HIV subject groups were similar in age, sex proportion, years of education, and proportion of APOE e4 carriers (table 1) . The 2 subject groups also had similar distributions of race and ethnicity, with predominantly white (52%-64% per group) or mixed-race (14%-22%) individuals and few blacks (0%-7%). Five subjects were APOE e4 homozygous, and all were HIVpositive (3 had HAND and 2 had no cognitive deficits). The 2 HIV1 groups (APOE e42 vs APOE e41) were not different in their CD4 counts, nadir CD4 count, log viral load, Karnofsky score, HIV dementia scale, or duration of HIV diagnosis. However, both HIV groups had more depressive symptoms on the Center for Epidemiological Studies-Depression Scale than the 2 SN groups, but they were not clinically depressed. Ten percent of the subjects (11 HIV, 6 SN) had nonsignificant incidental findings on MRI (data not shown).
Effects of HIV, APOE e4, and age on brain metabolites.
HIV1 subjects had higher frontal white matter MI than SN subjects, regardless of their APOE e41 status (110%, p 5 0.004) ( figure 1 ). However, individuals with APOE e41, both SN and HIV subjects, had slightly lower basal ganglia tCr (24%, p 5 0.05).
In the parietal cortex, the effect of APOE e41 differed between SN controls (higher MI) and HIV subjects (nonsignificantly lower MI); interaction p value 5 0.02. These findings remained unchanged after covarying for the percentage gray matter in each voxel. Furthermore, age-dependent changes in the frontal white matter MI were different across the 4 subject groups (interaction p 5 0.04, figure 1C, right). Both SN groups showed higher frontal white matter MI with older age. However, the slope is much steeper for those with e41 than e42 (age 3 e41 status interaction p 5 0.006), demonstrating an antagonistic pleiotropy effect only in APOE e41 SN subjects. In contrast, HIV subjects had elevated MI levels across the age span, and regardless of the APOE e41 status (age 3 APOE e41 status interaction p 5 0.44). The glial metabolites in other brain regions did not show significant group 3 age interactions.
Effects of HIV, APOE e4, and age on cognition. As expected, HIV subjects, regardless of APOE e41 status, performed significantly poorer than SN subjects on the majority of the cognitive domains, although the effect sizes were small in this cohort (table 2, figure 2 ). However, only HIV but not SN subjects with APOE e41 tended to perform worse than APOE e42 subjects on executive function, as exemplified by the Trail B task (table 2; figure 2, top graphs). Similar trends were observed for the fluency and memory domains, and the corresponding tests that contributed to the poorest performance in the HIV e41 subjects (table 2; figure 2, middle graphs). Because APOE e41 subjects additionally tended to perform worse than APOE e42 subjects on the attention/working memory domain (p 5 0.04), this led to an additive effect with HIV status. Consequently, HIV1 APOE e41 subjects showed the poorest attention/working memory performance (p , 0.0001), especially in the letter-number sequencing task (figure 2, bottom graphs). Furthermore, HIV1 APOE e41 subjects had persistently lower performance on these tests across the age span, except for Trail Making Test B, in which slower performance was found primarily in the oldest HIV1 APOE e41 subjects (figure e-1 on the Neurology ® Web site at Neurology.org).
Relationships between cognitive function and brain metabolite abnormalities. Subjects with higher frontal white matter MI had lower motor z scores, especially in the nondominant hand ( figure 3) . However, only APOE e41 subjects showed an association between higher parietal gray matter MI and poorer performance on the fluency domain (interaction p 5 0.009), especially those also HIV1, and slower speed of information processing scores (interaction p 5 0.009).
DISCUSSION This is the first study to evaluate the independent and combined effects of APOE e4 genotype and HIV infection on brain metabolite abnormalities, including age-dependent changes, of our primarily (.90%) cART-treated HIV subjects. We also delineated the combined effects of HIV and APOE e4 on cognitive performance and validated our hypothesis that HIV1 APOE e4 carriers have the poorest cognitive performance throughout the lifespan. Lastly, the relationship between neuroinflammation (elevated MI) and cognitive performance across the subject groups is evaluated. First, our primarily cART-treated HIV subjects showed persistent glial activation (with elevated MI) in the frontal white matter across the age span. This finding is consistent with that reported in prior MRS studies of patients with HIV, 15 in postmortem brains of patients with HIV, 16 and in Simian immunodeficiency virus-infected macaques. 17 Persistent glial activation is also reflected by elevated CSF chemokines and cytokines (e.g., inducible protein-10, interleukin [IL]-8, and monocyte chemoattractant protein-1), 18, 19 which are released by astrocytes and microglia, especially in HIV patients with higher ratios of MI/tCr. 19 However, APOE e4 had little additional influence on the elevated frontal white matter MI across the lifespan of the HIV subjects. This contrasts with the antagonistic pleiotropy effect of APOE e41 in SN subjects: lower MI at younger age but higher MI at older age compared with APOE e42 SN subjects. Furthermore, independent of HIV serostatus, subjects with APOE e4 showed tendencies for lower levels of tCr in the basal ganglia but higher concentrations of MI in the Correlations between MI levels and cognitive performance
Higher levels of the glial marker MI in the frontal WM were associated with slower fine motor tasks, whereas higher MI levels in the parietal cortex were associated with poorer performance on fluency and speed of information processing domains, especially in subjects with APOE e4 allele(s). FAS 5 Fluency and Verbal Fluency; GM 5 gray matter; MI 5 myo-inositol; SN 5 seronegative; WM 5 white matter.
parietal cortex across the age span. Collectively, these findings indicate that e41 allele(s) and HIV infection have independent and brain region-specific influence on energy metabolism and glial activation. The elevated MI in younger HIV subjects also suggests premature brain aging, because MI increases with normal aging. 20 Prematurely lower brain glutamate levels (possibly due to reduced reuptake and recycling of glutamate by activated astrocytes) 21 and prematurely reduced cognitive reserve were also reported in younger subjects with HAND. 22 However, in the parietal gray matter, elevated MI is found only in SN, but not HIV1, APOE e41 subjects. Elevated parietal MI is found in patients with AD, 23 and likely reflects greater microglial activation, especially in e41 individuals. 24 Likewise, ApoE4 mice displayed greater and more prolonged increases of cytokines (IL-1b, IL-6, tumor necrosis factor-a) than ApoE2-and ApoE3-expressing mice. 25 The lack of an e41-mediated inflammatory response in the parietal cortex of e41 HIV subjects may reflect microglial dystrophy due to the premature aging. In addition, the lower basal ganglia tCr in all e41 subjects is similar to that found in basal ganglia of ARV-naive HIV patients with severe dementia 26 and in occipital cortex of APOE e41 elderly without dementia. 27 Lower or depleted tCr in these conditions might result from the increased metabolic demands with chronic glial activation, especially in the basal ganglia, which have dense dopaminergic synapses.
Second, APOE e41 subjects had poorer attention and working memory than APOE e42 subjects, independent of HIV status. However, among the 4 groups, HIV1 APOE e41 subjects performed poorest on executive function, attention/working memory, fluency, and memory. APOE e41 negatively affects cognition in AD 28 and in other brain injuries, such as traumatic brain injury, 29 and younger individuals with MS. 30 However, the effects of APOE e4 allele on HAND were inconsistent among studies. [4] [5] [6] [7] [8] [9] [10] Several studies found that HIV1 APOE e4 carriers had increased risk of HAND, [5] [6] [7] [8] while others found increased risk only in older individuals ($50 years) 4 or no increased risk of HAND. 9,10 These conflicting findings may in part be attributable to the antagonistic pleiotropy effect of the APOE e4 allele(s), 11 which negatively affects older individuals but may enhance cognitive function in younger individuals. Hence, the negative effects of APOE e4 are evident only at older ages, as seen in most patients with AD. However, in some HIV-positive individuals, the negative effect of APOE e4 may emerge earlier because younger HIV1 APOE e4 carriers already showed brain atrophy and cognitive deficits. 5 In the current study, APOE e41 exacerbated the cognitive deficits in our HIV subjects across all ages, except for the performance on Trail B, which was slower only in older e41 HIV1 subjects. The poorer performance on some of the cognitive tasks in older HIV APOE e41 patients likely resulted from the lower cognitive reserve in the aging HIV-infected brain, especially those with HAND. 22 This finding is also consistent with the more widespread deficits in brain structural connectivity (on diffusion tensor imaging scans) in HIV1 APOE e4 subjects. 31 These discrepancies in the effects of APOE e4 on HAND may also be partly attributable to racial differences among cohorts. A large longitudinal study found that only white but not black individuals with APOE e41 showed faster decline in semantic and working memory. 32 Because the HIV subjects in the current study were primarily white, they might be more susceptible to the influence of APOE e41 allele(s) on attention/working memory.
The neuropathologic substrates for APOE e4mediated cognitive deficits in HIV patients are not well understood. However, APOE e41 HIV1 subjects showed greater atrophy in subcortical gray matter structures and white matter. 5 In addition, in postmortem HIV-infected brains, both APOE e4 and older age increased the likelihood of cerebral b-amyloid (Ab) plaque deposition (as diffuse plaques and mild to moderate amyloid angiopathy, but sparse phospho-tau neurofibrillary tangles), and only APOE e4 carriers with the Ab plaques had greater probability of HAND. 33 Furthermore, CSF ApoE protein was elevated only in HIV1 APOE e41 subjects, and the levels correlated with the severity of cognitive deficits, 8 suggesting that the aberrant ApoE e4 protein could not clear the Ab and contributed to HAND. Therefore, both AD and HAND subjects with APOE e4 may share similar mechanisms for excess accumulation of Ab, which would elicit neuroinflammation and release of inflammatory molecules. 34 Again, racial ancestry may also have an important role in how APOE e4 might be expressed since brain samples from individuals with greater genetically determined African ancestry had fewer neuritic plaques. 35 Lastly, neuroinflammation (higher MI) in the frontal white matter was associated with slower fine motor speed across all subjects, especially in the HIV1 APOE e41 subjects. Elevated glial marker MI has been associated with poorer cognitive performance in both ARV-naive 26 and ARV-stable patients with HIV. 15 Similarly, greater neuroinflammation (higher MI) in the parietal cortex was associated with poorer performance on verbal fluency, particularly in HIV1 APOE e41 subjects. These findings suggest that the neuroinflammatory responses resulting from HIV infection and APOE e4 allele(s) may lead to synergistic or additive effects on cognitive deficits. Conversely, the antagonistic pleiotropic effect of APOE e4 on MI in SN subjects suggests a protective or anti-inflammatory effect, with lower MI and better cognitive performance, in the younger SN APOE e41 subjects.
We had a moderately large sample size and a relatively higher proportion of APOE e4 subjects (28.9% of the SN group and 28.8% of the HIV group) compared with prior reported frequencies across different ethnic groups (12%-20%). 36 However, the small number of APOE e41 subjects led to only trends for HIV 3 APOE e4 interactions for many tests and was insufficient to evaluate a gene-dose effect (1 copy or 2 copies of APOE e4), the possible antiinflammatory effects of e2 and e3 alleles, or a possible racial ancestry effect. Future studies with a larger sample size of APOE e4 individuals are needed to validate our findings on the influence of APOE e4 in HIVassociated brain injury and HAND. Although we excluded many common potential confounds (e.g., hepatitis C, drug dependence), some individuals still might have abused drugs, which might contribute to even more neuroinflammation with further elevation of MI 37 and Alzheimer-like pathology (i.e., increased hyperphosphorylated tau). 38 cART prolongs the lives of patients with HIV and is the cornerstone for HIV prevention. However, stably cART-treated patients with HIV continue to show persistent glial activation (elevated MI) that might contribute to their cognitive deficits. In younger subjects with HIV, the persistent glial activation attenuated the protective antagonistic pleiotropic effects of APOE e4. HIV1 APOE e4 subjects also had greater cognitive deficits, which may further increase the risk of HAND with older age. APOE e4 allele(s) may be a useful genetic marker to identify white and mixed-race subjects with HIV at risk of cognitive decline.
